Home › Companies › VERA THERAPEUTICS INC. › 2024-2025

VERA THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and VERA THERAPEUTICS INC.’s Form 8-K, filed 2025-05-19 (Item 5.07 on EDGAR). Page generated 02 October 2026.

7Reported items
192Asset managers
1,559Fund votes
2025-05-14Meeting date

Proxy season: 2024-2025 2025-2026

Explore VERA THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by VERA THERAPEUTICS INC.

These tallies are VERA THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-05-19 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

VERA THERAPEUTICS INC. — official shareholder meeting results, meeting held 2025-05-14
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Marshall Fordyce, M.D.	49,472,959	--	--	5,393,304	1,795,714	Majority: yes
Elect Director: Beth Seidenberg, M.D.	49,033,555	--	--	5,832,708	1,795,714	Majority: yes
Elect Director: Kimball Hall	49,366,281	--	--	5,499,982	1,795,714	Majority: yes
Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm	56,649,390	3,556	9,031	--	--	Majority: yes
Proposal 3: Advisory Vote on Executive Compensation	52,984,920	1,876,215	5,128	--	1,795,714	Majority: yes

Source: VERA THERAPEUTICS INC., Form 8-K, filed with the SEC on 2025-05-19 — read the filing on EDGAR.

How asset managers voted at the VERA THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 192 asset managers that disclosed a VERA THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of VERA THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN THE PROXY STATEMENT.

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Combines 6 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 52,984,920AGAINST: 1,876,215

VERA THERAPEUTICS INC.’s own tally for this item (“Proposal 3: Advisory Vote on Executive Compensation”): 52,984,920 for, 1,876,215 against, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 63,774,158 outstanding shares: 83% for, 3% against (86% of the company cast a for/against vote).

The 192 asset managers below cast 97% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 95%

FOR: 94.9%AGAINST: 2.6%ABSTAIN: 2.5%NOT VOTED: 0.0%

Largest asset managers voting on “TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS, AS DISCLOSED IN ” at VERA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
T. Rowe Price	11,091,436	0	0	For
Fidelity	5,781,329	0	0	For
Avoro Capital Advisors LLC	5,202,377	0	0	For
BlackRock	3,094,506	2,291	0	For
Vanguard	2,938,802	0	0	For
State Street	2,709,058	551	0	For
Commodore Capital LP	2,225,000	0	0	For
Eversept Partners, LP	1,864,713	0	0	For
Vestal Point Capital, LP	1,680,012	0	0	For
SAMLYN CAPITAL, LLC	1,654,454	0	0	For
Federated Hermes	1,576,300	0	0	For
First Light Asset Management, LLC	1,570,885	0	0	For
Kynam Capital Management, LP	0	0	1,493,208	Abstain
Sofinnova Investments, Inc.	1,440,942	0	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,179,125	0	0	For
Voya	1,116,909	0	0	For
Charles Schwab	845,341	0	0	For
DEERFIELD MANAGEMENT COMPANY, L.P.	833,620	0	0	For
JENNISON ASSOCIATES LLC	770,948	0	0	For
PICTET ASSET MANAGEMENT SA	753,472	0	0	For
Logos Global Management LP	690,000	0	0	For
Woodline Partners LP	655,284	0	0	For
Siren, L.L.C.	655,228	0	0	For
American Century	0	628,913	0	Against
Victory Capital	582,346	0	0	For

Showing the 25 largest of 192 asset managers. See all 192 in the interactive database.

2. TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS.

SECTION 14A SAY-ON-PAY VOTES

Combines 5 wordings of this item as funds reported it.

99.9% fund support · no official result

ONE YEAR 63%1 YEAR 31%

The 185 asset managers below cast 99.9% of the shares they voted on this item FOR (1,926,033 for, 20 against).

FOR: 1,926,033 (3.3%)AGAINST: 20 (0.0%)ABSTAIN: 1,496,092 (2.6%)ONE YEAR: 36,638,681 (63.3%)1 YEAR: 17,827,933 (30.8%)3 YEARS: 19,761 (0.0%)THREE YEARS: 3,014 (0.0%)NOT VOTED: 150 (0.0%)1-YEAR: 122 (0.0%)

Largest asset managers voting on “TO INDICATE, ON AN ADVISORY BASIS, THE PREFERRED FREQUENCY OF STOCKHOLDER ADVISORY VOTES ON THE COMPENSATION O” at VERA THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
T. Rowe Price	0	0	One Year
Fidelity	0	0	One Year
Avoro Capital Advisors LLC	0	0	1 Year
BlackRock	0	0	1 Year
Vanguard	0	0	One Year
State Street	0	0	One Year
Commodore Capital LP	0	0	One Year
Vestal Point Capital, LP	0	0	One Year
SAMLYN CAPITAL, LLC	0	0	1 Year
Federated Hermes	0	0	1 Year
First Light Asset Management, LLC	1,570,885	0	For
Kynam Capital Management, LP	0	1,493,208	Abstain
Sofinnova Investments, Inc.	0	0	One Year
GEODE CAPITAL MANAGEMENT, LLC	0	0	One Year
Voya	0	0	One Year
Charles Schwab	0	0	1 Year
DEERFIELD MANAGEMENT COMPANY, L.P.	0	0	1 Year
JENNISON ASSOCIATES LLC	0	0	1 Year
PICTET ASSET MANAGEMENT SA	0	0	One Year
Logos Global Management LP	0	0	One Year
Woodline Partners LP	0	0	One Year
Siren, L.L.C.	0	0	1 Year
American Century	0	0	One Year
Victory Capital	0	0	One Year
ORBIMED ADVISORS LLC	0	0	1 Year

Showing the 25 largest of 185 asset managers. See all 185 in the interactive database.

3. To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of stockholders: Beth Seidenberg, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%11%

FOR: 49,033,555WITHHELD: 5,832,708

VERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Beth Seidenberg, M.D.”): 49,033,555 for, 5,832,708 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 63,774,158 outstanding shares: 77% for, 9% withheld (86% of the company cast a for/withheld vote).

The 58 asset managers below cast 100% of the shares they voted on this item FOR (15,788,113 for, 0 against).

FOR 94%

FOR: 15,788,113 (93.8%)ABSTAIN: 1,050,738 (6.2%)

Largest asset managers voting on “To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of sto” at VERA THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
T. Rowe Price	4,697,792	0	For
Fidelity	2,828,244	0	For
Vanguard	2,782,639	0	For
BlackRock	1,624,532	0	For
State Street	907,373	1,086	For
Federated Hermes	788,150	0	For
Voya	497,234	0	For
Charles Schwab	422,657	0	For
Prudential/PGIM	408,636	0	For
American Century	0	306,623	Abstain
Victory Capital	0	230,613	Abstain
John Hancock	188,941	15,818	For
Equitable	89,448	55,714	For
Bridge Builder Trust	8,756	95,430	Abstain
TIAA	100,347	0	For
Russell Investments	80,124	0	For
Thornburg	67,998	0	For
AIG/SunAmerica	0	60,758	Abstain
QUANTITATIVE MASTER SERIES LLC	60,347	0	For
DWS	0	51,343	Abstain
CARILLON SERIES TRUST	0	48,923	Abstain
ALPS ETF Trust	0	42,506	Abstain
Transamerica	39,915	0	For
Lincoln Financial	32,400	4,805	For
Lord Abbett	0	34,880	Abstain

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

4. To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of stockholders: Kimball Hall

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 49,366,281WITHHELD: 5,499,982

VERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Kimball Hall”): 49,366,281 for, 5,499,982 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 63,774,158 outstanding shares: 77% for, 9% withheld (86% of the company cast a for/withheld vote).

The 58 asset managers below cast 100% of the shares they voted on this item FOR (15,808,365 for, 0 against).

FOR 94%

FOR: 15,808,365 (93.9%)ABSTAIN: 1,030,486 (6.1%)

Largest asset managers voting on “To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of sto” at VERA THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
T. Rowe Price	4,697,792	0	For
Fidelity	2,828,244	0	For
Vanguard	2,782,639	0	For
BlackRock	1,624,532	0	For
State Street	907,373	1,086	For
Federated Hermes	788,150	0	For
Voya	497,234	0	For
Charles Schwab	422,657	0	For
Prudential/PGIM	408,636	0	For
American Century	0	306,623	Abstain
Victory Capital	0	230,613	Abstain
John Hancock	188,941	15,818	For
Equitable	89,448	55,714	For
Bridge Builder Trust	8,756	95,430	Abstain
TIAA	100,347	0	For
Russell Investments	80,124	0	For
Thornburg	67,998	0	For
AIG/SunAmerica	0	60,758	Abstain
QUANTITATIVE MASTER SERIES LLC	60,347	0	For
DWS	0	51,343	Abstain
CARILLON SERIES TRUST	0	48,923	Abstain
ALPS ETF Trust	0	42,506	Abstain
Transamerica	39,915	0	For
Lincoln Financial	32,400	4,805	For
Lord Abbett	0	34,880	Abstain

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

5. To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of stockholders: Marshall Fordyce, M.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

90% Majority: yes · of votes cast

FOR 90%10%

FOR: 49,472,959WITHHELD: 5,393,304

VERA THERAPEUTICS INC.’s own tally for this item (“Elect Director: Marshall Fordyce, M.D.”): 49,472,959 for, 5,393,304 withheld, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 63,774,158 outstanding shares: 78% for, 8% withheld (86% of the company cast a for/withheld vote).

The 58 asset managers below cast 100% of the shares they voted on this item FOR (15,849,445 for, 0 against).

FOR 94%

FOR: 15,849,445 (94.1%)ABSTAIN: 989,406 (5.9%)

Largest asset managers voting on “To elect the three Class I directors named below to hold office until the Company's 2028 annual meeting of sto” at VERA THERAPEUTICS INC., 2024-2025
Asset manager	For	Abstain	Vote
T. Rowe Price	4,697,792	0	For
Fidelity	2,828,244	0	For
Vanguard	2,782,639	0	For
BlackRock	1,624,532	0	For
State Street	907,373	1,086	For
Federated Hermes	788,150	0	For
Voya	497,234	0	For
Charles Schwab	422,657	0	For
Prudential/PGIM	408,636	0	For
American Century	0	306,623	Abstain
Victory Capital	0	230,613	Abstain
John Hancock	188,941	15,818	For
Equitable	130,528	14,634	For
Bridge Builder Trust	8,756	95,430	Abstain
TIAA	100,347	0	For
Russell Investments	80,124	0	For
Thornburg	67,998	0	For
AIG/SunAmerica	0	60,758	Abstain
QUANTITATIVE MASTER SERIES LLC	60,347	0	For
DWS	0	51,343	Abstain
CARILLON SERIES TRUST	0	48,923	Abstain
ALPS ETF Trust	0	42,506	Abstain
Transamerica	39,915	0	For
Lincoln Financial	32,400	4,805	For
Lord Abbett	0	34,880	Abstain

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

6. TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF KPMG LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2025.

AUDIT-RELATEDMajority of the votes cast: yes

99.9% Majority: yes · of votes cast

FOR 99.9%

FOR: 56,649,390AGAINST: 3,556

VERA THERAPEUTICS INC.’s own tally for this item (“Proposal 2: Ratification of the Appointment of Independent Registered Public Accounting Firm”): 56,649,390 for, 3,556 against, per its Form 8-K filed 2025-05-19 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 63,774,158 outstanding shares: 89% for, 0.1% against (89% of the company cast a for/against vote).

The 58 asset managers below cast 99.9% of the shares they voted on this item FOR (16,835,489 for, 478 against).

FOR 99.9%

FOR: 16,835,489 (100.0%)AGAINST: 478 (0.0%)ABSTAIN: 2,884 (0.0%)

Largest asset managers voting on “TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF KPMG LLP AS THE INDEPENDENT REGIST” at VERA THERAPEUTICS INC., 2024-2025
Asset manager	For	Vote
T. Rowe Price	4,697,792	For
Fidelity	2,828,244	For
Vanguard	2,782,639	For
BlackRock	1,624,532	For
State Street	908,459	For
Federated Hermes	788,150	For
Voya	497,234	For
Charles Schwab	422,657	For
Prudential/PGIM	408,636	For
American Century	306,623	For
Victory Capital	230,613	For
John Hancock	204,759	For
Equitable	145,162	For
Bridge Builder Trust	104,186	For
TIAA	100,347	For
Russell Investments	80,124	For
Thornburg	67,998	For
AIG/SunAmerica	60,758	For
QUANTITATIVE MASTER SERIES LLC	60,347	For
DWS	51,343	For
CARILLON SERIES TRUST	48,923	For
ALPS ETF Trust	42,506	For
Transamerica	39,915	For
Lincoln Financial	37,205	For
Lord Abbett	34,880	For

Showing the 25 largest of 58 asset managers. See all 58 in the interactive database.

7. Advisory Vote on Say on Pay Frequency

SECTION 14A SAY-ON-PAY VOTES

— fund support · no official result

ONE YEAR 100%

No shares were cast for or against this item by the managers below — every disclosed position was an abstention or was not voted.

ONE YEAR: 2,013,098 (100.0%)

Largest asset managers voting on “Advisory Vote on Say on Pay Frequency” at VERA THERAPEUTICS INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
Eversept Partners, LP	0	0	0	0	One Year
EFG Asset Management (North America) Corp.	0	0	0	0	One Year
JPMorgan	0	0	0	0	One Year
Desjardins Global Asset Management Inc.	0	0	0	0	One Year

Largest VERA THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked by the number of VERA THERAPEUTICS INC. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 63,774,158 shares outstanding at the time of that meeting.

Top VERA THERAPEUTICS INC. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	T. Rowe Price	17.39%
2	Fidelity	9.07%
3	Avoro Capital Advisors LLC	8.16%
4	BlackRock	4.86%
5	Vanguard	4.61%
6	State Street	4.25%
7	Commodore Capital LP	3.49%
8	Eversept Partners, LP	2.92%
9	Vestal Point Capital, LP	2.63%
10	SAMLYN CAPITAL, LLC	2.59%

Reported VERA THERAPEUTICS INC. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

VERA THERAPEUTICS INC. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Avoro Capital Advisors LLC	8.80%	13G
T. Rowe Price	7.46%	13F
BlackRock	6.26%	13F
Deep Track Capital, LP	6.15%	13G
Deerfield Mgmt, L.P.	5.25%	13G
FMR (Fidelity)	5.07%	13F
Vanguard Group	4.58%	13F
Sofinnova Venture Partners X, L.P. ("SVP X")	4.38%	13D
State Street	3.27%	13F
Point72 Asset Management, L.P.	1.93%	13G

Percentages above are of 63,774,158 shares outstanding, as reported by VERA THERAPEUTICS INC. on its Form 10-Q dated 2025-05-01 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from VERA THERAPEUTICS INC.’s 10-Q dated 2025-05-01. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At VERA THERAPEUTICS INC.'s shareholder meeting held 2025-05-14, in the 2024-2025 proxy season, 192 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,559 separate fund positions. Their filings are grouped here into 7 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS… — FOR was 97% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: VERA THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-05-19.

VERA THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.